Non-formulary brodalumab (Siliq®) will be covered on the prescription drug benefit when the following criteria are met:

- Documented diagnosis of Psoriasis on problem list
  - AND -
- Prescriber is a Dermatologist
  - AND -
- Patient does not have a diagnosis of Crohn’s disease
  - AND -
- Prescriber agrees to participate in Siliq REMS Program and to monitor for onset of suicidal ideation and behavior and discontinue if necessary
  - AND -
- Inadequate response, adverse reaction, or contraindication to 2 of the following:
  - acitretin
  - cyclosporine
  - methotrexate
  - phototherapy
  - AND -
- Inadequate response or contraindication to 5 of the following:
  - adalimumab (Humira)
  - apremilast (Otezla)
  - etanercept (Enbrel)
  - infliximab (Remicade) or infliximab product
  - secukinumab (Cosentyx) or ixekizumab (Taltz)
  - ustekinumab (Stelara)